BACKGROUND: Post-treatment contralateral hemiliver hypertrophy has created an interest in lobar liver radioembolization (RE) as a pre-surgery tool. METHODS: Liver and spleen volumes and function were studied in 83 patients submitted to partial liver volume RE at 4-8 weeks (T1), 10-26 weeks (T2), and >26 weeks (T3) after RE. RESULTS: More than half of the patients had cirrhosis with hepatocellular carcinoma. The main finding was a progressive increase in the volume of the spared hemiliver (mean absolute increase at T3: 230 ml). The percentage of patients in whom the baseline ratio of spared volume to total liver volume was <40% dropped from 56.6% at baseline to 29.4% at T2 (P < 0.001). A significant and progressive increase in spleen volume but not in portal vein diameter was also observed. A small percentage of patients developed hypersplenism, mostly those without cirrhosis (16.0% at T2). Six patients (five with portal vein thrombosis, cirrhosis or both) developed signs of portal hypertension by T2. CONCLUSIONS: The present results warrant further studies to better elucidate the mechanism underlying this phenomenon of spared hemiliver hypertrophy and to investigate its role as an alternative to portal vein embolization in the management of patients with potentially resectable liver tumours.
BACKGROUND: Post-treatment contralateral hemiliver hypertrophy has created an interest in lobar liver radioembolization (RE) as a pre-surgery tool. METHODS: Liver and spleen volumes and function were studied in 83 patients submitted to partial liver volume RE at 4-8 weeks (T1), 10-26 weeks (T2), and >26 weeks (T3) after RE. RESULTS: More than half of the patients had cirrhosis with hepatocellular carcinoma. The main finding was a progressive increase in the volume of the spared hemiliver (mean absolute increase at T3: 230 ml). The percentage of patients in whom the baseline ratio of spared volume to total liver volume was <40% dropped from 56.6% at baseline to 29.4% at T2 (P < 0.001). A significant and progressive increase in spleen volume but not in portal vein diameter was also observed. A small percentage of patients developed hypersplenism, mostly those without cirrhosis (16.0% at T2). Six patients (five with portal vein thrombosis, cirrhosis or both) developed signs of portal hypertension by T2. CONCLUSIONS: The present results warrant further studies to better elucidate the mechanism underlying this phenomenon of spared hemiliver hypertrophy and to investigate its role as an alternative to portal vein embolization in the management of patients with potentially resectable liver tumours.
Authors: Thomas M van Gulik; Jacomina W van den Esschert; Wilmar de Graaf; Krijn P van Lienden; Olivier R C Busch; Michal Heger; Otto M van Delden; Johan S Laméris; Dirk J Gouma Journal: Dig Surg Date: 2009-02-12 Impact factor: 2.588
Authors: Ricarda Seidensticker; Max Seidensticker; Robert Damm; Konrad Mohnike; Kerstin Schütte; Peter Malfertheiner; Mark Van Buskirk; Maciej Pech; Holger Amthauer; Jens Ricke Journal: Cardiovasc Intervent Radiol Date: 2011-10-26 Impact factor: 2.740
Authors: Maarten L J Smits; Peter Vanlangenhove; Emiel J C Sturm; Maurice A A J van den Bosch; Monirath Hav; Marleen Praet; Maarten A D Vente; Frédéric R Snaps; Luc Defreyne Journal: Cardiovasc Intervent Radiol Date: 2011-10-07 Impact factor: 2.740
Authors: S Hayashi; Y Baba; K Ueno; M Nakajo; F Kubo; S Ueno; T Aikou; T Komokata; N Nakamura; R Sakata Journal: Acta Radiol Date: 2007-09 Impact factor: 1.990
Authors: Alexander Villalobos; Mohamed M Soliman; Bill S Majdalany; David M Schuster; James Galt; Zachary L Bercu; Nima Kokabi Journal: Semin Intervent Radiol Date: 2020-12-11 Impact factor: 1.513
Authors: Jin-Yao Teo; John C Allen; David C Ng; Su-Pin Choo; David W M Tai; Jason P E Chang; Foong-Khoon Cheah; Pierce K H Chow; Brian K P Goh Journal: HPB (Oxford) Date: 2015-12-11 Impact factor: 3.647
Authors: Andrew Kennedy; Daniel B Brown; Jonas Feilchenfeldt; John Marshall; Harpreet Wasan; Marwan Fakih; Peter Gibbs; Alexander Knuth; Bruno Sangro; Michael C Soulen; Gianfranco Pittari; Ricky A Sharma Journal: J Gastrointest Oncol Date: 2017-12
Authors: Alessandro Cucchetti; Alberta Cappelli; Giorgio Ercolani; Cristina Mosconi; Matteo Cescon; Rita Golfieri; Antonio Daniele Pinna Journal: Liver Cancer Date: 2016-09-14 Impact factor: 11.740